Tamara A. Ranalli Net Worth

Insiders trading at QuidelOrtho

Over the last 21 years, insiders at QuidelOrtho have traded over $509,235,797 worth of QuidelOrtho stock and bought 304,015 units worth $10,385,234 . The most active insiders traders include Jack W Schuler, Matthew Strobeck, eGroup Inc.Carlyle Holdings .... On average, QuidelOrtho executives and independent directors trade stock every 16 days with the average trade being worth of $1,246,606. The most recent stock trade was executed by Group Inc.Carlyle Holdings ... on 9 August 2024, trading 74,134 units of QDEL stock currently worth $3,078,785.

What does QuidelOrtho do?

QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.

QuidelOrtho executives and stock owners

QuidelOrtho executives and other stock owners filed with the SEC include:

• Douglas Bryant,
  President, Chief Executive Officer, Director
• Douglas C. Bryant,
  Pres, CEO & Director
• Randall Steward,
  Chief Financial Officer
• Michael Abney,
  Senior Vice President - Distribution
• Robert Bujarski,
  Chief Operating Officer
• Ratan Borkar,
  Senior Vice President - International Commercial Operations
• Werner Kroll,
  Senior Vice President - R&D
• Edward Russell,
  Senior Vice President - Business Development
• Robert J. Bujarski,
  Chief Operating Officer
• Randall J. Steward,
  Chief Financial Officer
• Dr. Werner Kroll,
  Sr. VP of R&D
• Ratan S. Borkar,
  Sr. VP of International Commercial Operations
• Robert J. Bujarski J.D.,
  Pres & COO
• Kenneth Buechler,
  Independent Chairman of the Board
• Edward Michael,
  Independent Director
• Ken Widder,
  Independent Director
• Charles Slacik,
  Independent Director
• Matthew Strobeck,
  Independent Director
• Mary Polan,
  Independent Director
• Kathy Ordonez,
  Independent Director
• Ruben Argueta,
  Director - Investor Relations
• Ann Rhoads,
  Director
• Karen Gibson,
  Senior Vice President, Information Systems and Business Transformation
• Dr. Chockalingam Palaniappan Ph.D.,
  Chief Innovation Officer
• Patrick E. Klein,
  Chief Admin. Officer
• Louise Brandy,
  Chief Information Officer
• Rhys de Callier,
  VP of Strategy & Portfolio Management
• Dr. Johannes Kehle,
  Pres of AnDiaTec Division
• Phillip S. Askim,
  VP, Associate Gen. Counsel & Sec.
• Michael S. Iskra,
  Chief Commercial Officer
• Joseph M. Busky CPA,
  Chief Financial Officer
• Karen C. Gibson,
  Sr. VP of Digital Health Bus. Unit
• Edward Keith Russell,
  Sr. VP of Bus. Devel.
• Michael Donald Abney Jr.,
  Sr. VP of North American Sales & Distribution
• Michelle A. Hodges,
  Sr. VP & Gen. Counsel
• Group Inc.Carlyle Holdings ...,
  
• Thomas D Brown,
  Director
• Rodney F Dammeyer,
  Director
• John Tamerius,
  Sr. VP - Clinical/Reg Affairs
• Patrick Klein,
  Chief Administrative Officer
• Louise Brandy,
  SVP, Chief Information Officer
• Tamara A. Ranalli,
  SVP, Molecular Bus. Unit
• Mark W Smits,
  SVP-Commercial Operations
• Mark Pulido,
  Director
• John Matthew Radak,
  Chief Financial Officer
• Timothy Todd Stenzel,
  Chief Science Officer
• Scot M Mc Leod,
  Sr. VP - Operations
• Caren L Mason,
  President and CEO
• Jack W Schuler,
  Director
• Thomas James Foley,
  Chief Technical Officer
• David R. Scholl,
  Senior Vice President
• Richard C Iii Tarbox,
  Sr. VP - Corporate Development
• Matthew T Heindel,
  Sr. VP - Global Sales & Mrktg
• Douglas S Harrington,
  Director
• Faye Wattleton,
  Director
• Mark Paiz,
  Senior Vice President
• Thomas A Glaze,
  Director
• Paul E Landers,
  Sr. V.P., CFO and Secretary
• S Wayne Kay,
  President & CEO
• William J. Ferenczy,
  SVP, Cardio/Metabolic Unit
• Michael S. Iskra,
  EVP & CCO
• Christopher M Smith,
  Director
• Joseph D Jr. Wilkins,
  
• Evelyn S Dilsaver,
  
• Joseph M Busky,
  Chief Financial Officer
• James Prutow,
  
• Michelle A. Hodges,
  SVP, General Counsel